US4292300A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Controlled release suppositories
Assignee: Aventis Pharmaceuticals Inc
•
Filing: 1977-07-20
•
Granted: 1981-09-29
•
Expires: 1997-07-20
Abstract
Abstract A slow-release suppository is provided. The slow-release suppository comprises a linear polymer, water and a therapeutically active ingredient.
Inventors
- 👤 Geoffry A. Byrne
- 👤 Ross I. Aylott
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-27 07:22
CPC Classifications
A; A61; A61K; A61K9/00; A61K9/02
Claims Analysis
Total Claims: 7
Claim 1
Independent Claim
37 words
A non-dissolving, non-disintegrating slow-release suppository consisting essentially of methyl cellulose, water, and a therapeutically effective amount of a water-soluble therapeutically active ingredient wherein the water is present in an amount of more than 35 parts by weight.
Claim 2
Dependent Claim
37 words
A non-dissolving, non-disintegrating slow-release suppository consisting essentially of methyl cellulose, water, and a therapeutically effective amount of a water-soluble therapeutically active ingredient wherein the water is present in an amount of more than 35 parts by weight.
Claim 3
Dependent Claim
38 words
The slow-release suppository according to claim 1, wherein the amount of methyl cellulose is from about 30 to about 65 parts by weight, and the amount of water is from about 35 to about 70 parts by weight.
Claim 4
Dependent Claim
36 words
The slow-release suppository according to claim 2, wherein the amount of methyl cellulose is from about 30 to 60 parts by weight, and the amount of water is from about 40 to 70 parts by weight.
Claim 5
Dependent Claim
30 words
The slow-release suppository according to claim 3, wherein the amount of methyl cellulose is, essentially, 50 parts by weight, and the amount of water is, essentially, 50 parts by weight.
Claim 6
Dependent Claim
20 words
The slow-release suppository according to claim 4, wherein the methyl cellulose has a molecular weight between about 100,000 and 300,000.
Claim 7
Dependent Claim
42 words
A slow-release suppository according to claim 1, wherein the therapeutically active ingredient is selected from the group consisting of lignocaine hydrochloride, phenylephrine chloride, betamethasone sodium phosphate, sodium prednisolone metasulphobenzoate, di-sodium prednisolone phosphate, methylprednisolone sodium succinate, dexamethasone sodium phosphate and hydrocortisone sodium phosphate.
References Cited (Backward Citations)
US108034A
Cited
US1858108A
Cited
US2149005A
Cited
US2155658A
Cited
US2160503A
Cited
US2498374A
Cited
US2524416A
Cited
US2594439A
Cited
US2726982A
Cited
US2798838A
Cited
US3234091A
Cited
US3079303A
Cited
US3108043A
Cited
US3170464A
Cited
AU265647B2
Cited
US3134720A
Cited
US3440320A
Cited
US3336139A
Cited
US3493407A
Cited
US3449489A
Cited
US3496938A
Cited
US3443563A
Cited
GB1171691A
Cited
US3763861A
Cited
US3870790A
Cited
GB1279214A
Cited
US3640741A
Cited
US3767784A
Cited
GB1405088A
Cited
US3767789A
Cited
US4024073A
Cited
US3875300A
Cited
US3776001A
Cited
US4136162A
Cited
US4136145A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1984-09-28 | 1985-03-30 | 1985-09-29 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1988-09-28 | 1989-03-30 | 1989-09-29 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 1992-09-28 | 1993-03-30 | 1993-09-29 | $7700.00 | Window Closed / Lapsed |